Skip to main content

Table 5 Adverse event profile for FTD/TPI in mCRC patients with ECOG ≥2

From: Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer

Patient No.a

ECOG

MedDRA Preferred Term

Adverse Drug Reaction

1

2

Death

Non-related

Serious

Oedema peripheral

Non-related

Non-serious

Skin ulcer

Non-related

Non-serious

General physical health deterioration

Non-related

Non-serious

6b

2

Cough

Non-related

Non-serious

Fatigue

Non-related

Serious

Oesophagitis

Suspected

Serious

37

2

Urinary tract infection

Non-related

Non-serious

45

2

Abdominal Pain

Non-related

Non-serious

Anaemia

Suspected

Serious

Constipation

Non-related

Non-serious

Leukopenia

Suspected

Serious

Thrombocytopenia

Suspected

Serious

Urinary tract infection

Suspected

Serious

85

2

Metastases to central nervous system

Non-related

Non-serious

152b

3

Dyspnoea

Non-related

Non-serious

210

2

Dyspnoea

Non-related

Non-serious

Fatigue

Non-related

Serious

Oedema peripheral

Non-related

Non-serious

General physical health deterioration

Non-related

Non-serious

230

2

Thrombocytopenia

Suspected

Serious

Leukopenia

Suspected

Serious

Nausea

Non-related

Non-serious

248

3

Nausea

Non-related

Non-serious

  1. aFor 13 mCRC patient (ECOG ≥2) no. 21, 49, 68, 138, 188, 192, 219, 222, 226, 250, 251, 255 and 257 no data of adverse events are available
  2. bmCRC patients (ECOG ≥2) with prior Regorafenib treatment